Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;4(4):227-9.

The role of oxytocin antagonists in repeated implantation -failure

W Decleer  1 , K Osmanagaoglu  1 , P Devroey  2
Affiliations

The role of oxytocin antagonists in repeated implantation -failure

W Decleer et al. Facts Views Vis Obgyn. 2012.

Abstract

A prospective cohort study has been performed to find out if the administration of an oxytocin antagonist (Atosiban) at the occasion of embryo transfer has an effect on the pregnancy rate in patients with repeated failure of implantation. A total of 52 women with repeated failure of implantation after IVF/ICSI were included in this study. The ongoing pregnancy rate (OPR) in the total group of patients was 12 out of 52 (23.1%). Based on embryo quality all cases were categorized in two groups. One with good embryo quality (Group A) and one with poor quality embryos (Group B). Of all patients who became pregnant, 11 belonged to the group of 26 patients with good quality embryos (OPR 42.3 %) and only one to the group of 26 patients with poor quality embryos (OPR 3.8 %). Our results indicate that when good quality embryos can be obtained, the use of Atosiban at the occasion of embryo transfer might offer a significant better implantation rate in women with repeated implantation failure after IVF/ICSI.

Keywords: Atosiban; IVF-embryo transfer; embryo quality; implantation rate; ongoing pregnancy rate; uterine contractibility.

PubMed Disclaimer

References

    1. Baczkowski T, Kurzawa R, Glabowski W. Methods of embryo scoring in in vitro fertilization. Biol. Reprod. 2004;4:5–22. - PubMed
    1. European Medicines Agency. Tractocile (atosiban) – European public assessment report revision 12. http://www.ema.europa. eu/humandocs/Humans/EPAR/tractocile/tractocile.htm European Medicines Agency. 2009
    1. Fanchin R, Righini C, Olivennes F, et al. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum Reprod. 1998;13:1968–1974. - PubMed
    1. Kyrou D, Todorovic B, Fatemi HM, et al. Does the estradiol level on the day of human chorionic gonadotrophin administration have impact on pregnancy rates in patients treated with rec-FSH/ GnRH antagonist? Hum Reprod. 2009;24:2902–2909. - PubMed
    1. Lan VT, Khang VN, Nhu GH, et al. Atosiban improves implantation and pregnancy rates in patients with repeated failure of implantation. Reprod Biomed Online. 2012;25:254–260. - PubMed

LinkOut - more resources